Abstract
Background Tumor resistance to neoadjuvant chemotherapy (NAC) is the major cause of therapy failure in breast cancer (BC) patients. So far, 99mTc-sestamibi (MIBI) is the most widely used non-Positron Emission Tomography tracer in BC. MIBI uptake is known to be an independent prognostic factor in BC, whereas increased tumor uptake and retention of MIBI is associated with better response to chemotherapy. A rapid washout of MIBI appears to correlate with chemoresistance. Recent improvements in Single-Photon Emission Computed Tomography (SPECT) reconstructions enable us to quantify MIBI uptake and retention and to study metabolic parameters to define their role in therapy monitoring. The aim of this study is to assess the accuracy of a new absolute quantitative image reconstruction technique (QMetrix®, GE Healthcare) in locally advanced breast cancer (LABC) using prone SPECT/Computed Tomography (CT).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
